For decades, clinicians have relied on cardiac troponin as the central biochemical signal of heart-muscle injury. When troponin levels rise sharply, the result can point toward an acute myocardial infarction. The harder problem begins when the increase is small, persistent, or hidden within the broad range considered “normal.” In patients with stable coronary artery disease, the arteries may be narrowed without causing an active heart attack, and conventional troponin measurements can struggle to distinguish disease-related biological signals from differences in heart size, age, sex, kidney function, and other sources of chronic cardiac stress. A new study by S. Fathieh, M.P. Gray, O. Tang and colleagues examines whether that diagnostic gap can be narrowed by interpreting high-sensitivity cardiac troponin I in relation to the amount of heart muscle producing it.
Published in Nature Cardiovascular Research, the study investigates the utility of high-sensitivity cardiac troponin I normalized to left ventricular mass for detecting stable coronary artery disease. The idea is deceptively simple: rather than viewing a troponin concentration as an isolated number, researchers relate it to the mass of the left ventricle, the chamber responsible for pumping oxygenated blood through the systemic circulation. The left ventricle is also the portion of the heart most directly exposed to pressure overload and ischemic stress. Its size varies substantially between individuals, and that variation may influence the amount of troponin released into the bloodstream even when the underlying degree of disease is similar. Normalization could therefore provide a more biologically informed measurement than a raw concentration alone.
High-sensitivity cardiac troponin assays have transformed cardiovascular diagnostics because they can detect concentrations far below the limits of earlier tests. Troponin I is a protein found in the contractile apparatus of cardiac muscle cells. When these cells are damaged, even microscopically, fragments of the protein can enter the circulation. In acute coronary syndromes, the pattern is often dramatic: concentrations rise and fall over time, reflecting active injury. Stable coronary artery disease is different. Atherosclerotic plaques may restrict blood flow, and the heart may experience repeated episodes of supply-demand imbalance during exertion, without producing the large, rapidly changing troponin release associated with an infarction. The resulting concentrations can be low but clinically meaningful, creating a measurement challenge precisely where early identification could influence prevention and treatment.
The study’s central contribution is to place that low-level signal in the anatomical context of ventricular mass. A person with a larger left ventricle has more myocardium and potentially more cardiac cells capable of releasing troponin. Conversely, the same measured concentration may represent a different biological burden in a person with a smaller ventricle. Left ventricular hypertrophy, which can develop in response to high blood pressure, aortic valve disease, or other conditions, may further complicate interpretation. If two patients have identical high-sensitivity troponin I values but markedly different ventricular masses, treating those values as equivalent could obscure risk. By expressing troponin relative to left ventricular mass, the investigators test whether the signal becomes more closely linked to the presence of obstructive or otherwise clinically relevant coronary disease.
To establish whether the adjusted marker improves detection, the researchers compared troponin measurements with cardiac structural information and assessments of coronary artery disease. The approach reflects a broader shift in cardiovascular medicine toward combining molecular biomarkers with imaging rather than asking one test to answer every question. High-sensitivity troponin supplies a biochemical readout of myocardial stress or injury, while imaging can quantify the mass of the ventricle and evaluate the coronary arteries. When those data are integrated, clinicians may gain a more precise picture of how much cardiac tissue is exposed to disease and whether the observed biomarker level is disproportionate to the size of the heart. The analysis therefore focuses not only on whether troponin is detectable, but also on whether its interpretation changes when adjusted for a measurable feature of cardiac anatomy.
This distinction matters because stable coronary disease often exists along a continuum rather than as a binary condition. Some patients have plaque without significant blood-flow limitation; others have narrowing that becomes important during exertion; still others have diffuse disease affecting several vessels. Symptoms can be equally variable, ranging from classic exertional chest discomfort to breathlessness, fatigue, or no symptoms at all. Traditional risk factors such as diabetes, smoking, hypertension, high cholesterol, and advancing age remain essential, but they do not reveal how the heart is responding to the disease at a given moment. A biomarker that captures subtle myocardial injury could add a dynamic layer to risk assessment. Normalization to left ventricular mass may help prevent that signal from being diluted by anatomical differences between patients.
The work also illustrates why “normal” laboratory values are not always biologically universal. Reference ranges for high-sensitivity troponin are typically established using selected populations and may be influenced by sex, age, renal function, and coexisting structural heart disease. Troponin concentrations can rise in chronic kidney disease, heart failure, atrial fibrillation, pulmonary disease, and strenuous physical activity, even without an acute coronary blockage. At the same time, a value below a conventional diagnostic threshold does not necessarily mean that the myocardium is entirely unaffected. The investigators’ normalization strategy does not eliminate these confounders, nor is it intended to replace clinical judgment. Instead, it addresses one specific source of variation: the quantity of left ventricular muscle underlying the circulating signal.
The implications extend beyond a new formula. If validated across different populations and clinical settings, a mass-adjusted troponin measurement could support more individualized triage for patients with suspected but stable coronary disease. It might help identify people who would benefit from anatomical imaging, functional stress testing, or more intensive preventive therapy, while reducing unnecessary investigations in those whose low-level troponin signal is proportionate to their cardiac structure and overall risk. Such a tool could be especially useful in patients with left ventricular hypertrophy, where a raw troponin value may be difficult to interpret. However, the test would still need rigorous calibration, standardized imaging protocols, and clear thresholds before it could be integrated into routine care. A promising association is not the same as a universally deployable diagnostic rule.
There are also practical questions that the study brings into sharp focus. Left ventricular mass is usually estimated with echocardiography or cardiac magnetic resonance imaging, and the values can differ according to the imaging method, the mathematical formula used, and the quality of the images. Cardiac magnetic resonance is highly reproducible but less accessible and more expensive than echocardiography. If mass normalization is to become a widely used clinical strategy, researchers will need to determine whether simpler imaging methods provide sufficient accuracy. They must also test the approach in ethnically diverse populations, across a broad range of body sizes and ages, and among people with kidney disease, heart failure, diabetes, and other conditions that influence troponin. Most importantly, future studies will need to show whether the adjusted marker improves patient outcomes, not merely statistical discrimination between groups.
For now, the study offers a compelling example of how cardiovascular diagnostics may evolve from fixed cutoffs toward biologically contextualized measurements. A high-sensitivity troponin result is not simply a number floating in the bloodstream; it is a signal generated by a particular heart, with a particular mass, structure, workload, and disease history. Relating troponin I to left ventricular mass could make that signal easier to interpret in stable coronary artery disease, where conventional testing often operates at the limits of sensitivity. The approach does not turn a blood test into a standalone diagnosis, and it cannot replace imaging or clinical assessment. But by connecting molecular evidence of myocardial injury with the anatomy of the heart itself, Fathieh, Gray, Tang and colleagues point toward a more personalized way to detect coronary disease before it announces itself as an emergency.
Subject of Research: Detection of stable coronary artery disease using high-sensitivity cardiac troponin I normalized to left ventricular mass
Article Title: Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease
Article References: Fathieh, S., Gray, M.P., Tang, O. et al. Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease. Nat Cardiovasc Res 5, 763–776 (2026). https://doi.org/10.1038/s44161-026-00837-z
Image Credits: AI Generated
DOI: 10.1038/s44161-026-00837-z
Keywords: high-sensitivity cardiac troponin I, left ventricular mass, stable coronary artery disease, cardiovascular biomarkers, myocardial injury, cardiac imaging, coronary atherosclerosis, precision medicine
